Abstract
Regression of rectal carcinoma following preoperative chemoradiotherapy is highly variable. No reliable predictors of treatment response are yet known, and existing systems for quantifying tumour regression are suboptimal. This project sought to better define regression and its relationship to clinical outcomes, and to investigate potential predictors of regression. Regression was shown to be a significant predictor of clinical outcome, and a new method of assessing tumour regression was attempted.
Expression of SPARC protein in pre-treatment biopsies was associated with subsequent regression. If verified, this will be the first identified predictive marker for tumour resonse to neoadjuvant chemoradiotherapy in rectal cancer.
Expression of SPARC protein in pre-treatment biopsies was associated with subsequent regression. If verified, this will be the first identified predictive marker for tumour resonse to neoadjuvant chemoradiotherapy in rectal cancer.
| Original language | English |
|---|---|
| Awarding Institution |
|
| Supervisors/Advisors |
|
| Award date | 22 Jun 2018 |
| DOIs | |
| Publication status | Unpublished - 2018 |
Access to Document
- THESIS - DOCTOR OF PHILOSOPHY - HEMMINGS Christine Tracey - 2018
This work is protected by Copyright. You may print or download ONE copy of this document for the purpose of your own non-commercial research or study. Any other use requires permission from the copyright owner. The Copyright Act requires you to attribute any copyright works you quote or paraphrase.